We reviewed the incidence and the impact of posttransplant lymphoproliferative disorders (PTLDs) on patient survival among a consecutive series of 255 patients. Five cases of PTLD were observed in adults: two cases were early (less than 1 year) and three cases, late lymphomas. The EBV positivity and the degree of immunosuppression were the main risk factors. We labeled cases as early or late according to whether the time elapsed from the transplant to the first clinical evidence of PTLD was less than 12 months. The median time from transplant to diagnosis of PTLD was 8 (early) and 108 (late) months. All cases were treated by reduction in immunosuppressive therapy with conventional chemotherapy and rituximab. The early cases with lymphoma located at the hepatic hilum died due to local complications (biliary sepsis and hemobilia), after an initial partial response to chemotherapy. The three patients with late cases are in remission after a mean follow-up of 23 months.
Avolio, A. W., Agnes, S., Barbarino, R., Magalini, S., Frongillo, F., Pagano, L., Larocca, L. M., Pompili, M., Caira, M., Sollazzi, L., Castagneto, M., Posttransplant lymphoproliferative disorders after liver transplantation: analysis of early and late cases in a 255 patient series, <<TRANSPLANTATION PROCEEDINGS>>, 2007; 39 (6): 1956-1960. [doi:10.1016/j.transproceed.2007.05.019] [http://hdl.handle.net/10807/14229]
Posttransplant lymphoproliferative disorders after liver transplantation: analysis of early and late cases in a 255 patient series
Avolio, Alfonso Wolfango;Agnes, Salvatore;Barbarino, Raffaella;Magalini, Sabina;Frongillo, Francesco;Pagano, Livio;Larocca, Luigi Maria;Pompili, Maurizio;Caira, Morena;Sollazzi, Liliana;Castagneto, Marco
2007
Abstract
We reviewed the incidence and the impact of posttransplant lymphoproliferative disorders (PTLDs) on patient survival among a consecutive series of 255 patients. Five cases of PTLD were observed in adults: two cases were early (less than 1 year) and three cases, late lymphomas. The EBV positivity and the degree of immunosuppression were the main risk factors. We labeled cases as early or late according to whether the time elapsed from the transplant to the first clinical evidence of PTLD was less than 12 months. The median time from transplant to diagnosis of PTLD was 8 (early) and 108 (late) months. All cases were treated by reduction in immunosuppressive therapy with conventional chemotherapy and rituximab. The early cases with lymphoma located at the hepatic hilum died due to local complications (biliary sepsis and hemobilia), after an initial partial response to chemotherapy. The three patients with late cases are in remission after a mean follow-up of 23 months.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.